Inicio
Resultado de la búsqueda
2 búsqueda de la palabra clave 'Sacral neuromodulation'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Título : Overactive bladder - 18 years - Part I Tipo de documento : documento electrónico Autores : Juan Carlos Castaño Botero, Fecha de publicación : 2016 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics Resumen : Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):188-98. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0365 PMID : 27176184 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3981 Overactive bladder - 18 years - Part I [documento electrónico] / Juan Carlos Castaño Botero, . - 2016.
Obra : International Brazilian Journal of Urology
Idioma : Inglés (eng)
Palabras clave : Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics Resumen : Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):188-98. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0365 PMID : 27176184 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3981 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000573 AC-2016-048 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2016-048.pdfAdobe Acrobat PDF
Título : Overactive bladder - 18 years - Part II Tipo de documento : documento electrónico Autores : Juan Carlos Castaño Botero, Fecha de publicación : 2016 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics Resumen : Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0367 PMID : 27176185 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3980 Overactive bladder - 18 years - Part II [documento electrónico] / Juan Carlos Castaño Botero, . - 2016.
Obra : International Brazilian Journal of Urology
Idioma : Inglés (eng)
Palabras clave : Overactive Bladder Muscarinic Antagonists Beta-adrenergic agonists Botulinum Toxin Sacral neuromodulation Urodynamics Resumen : Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0367 PMID : 27176185 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3980 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000572 AC-2016-047 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2016-047.pdfAdobe Acrobat PDF
